Tysabri and Progressive Multifocal Leukoencephalopathy: What Is the Timeline?

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Communication to Targeted Risk Assessment

If you or a loved one is taking Tysabri, you may have heard about the risk of progressive multifocal leukoencephalopathy (PML) — a rare but serious brain infection. Decades of pharmacovigilance have established that PML typically follows a predictable timeline after JC virus reactivation. This page outlines the recognized stages, from viral activation to clinical symptoms, and explains how monitoring can help detect PML early.

Find Out If You Qualify for Compensation →

Bridging Clinical Evidence and Occupational Exposure Concerns

The established clinical evidence linking Tysabri to PML provides a foundation for considering potential risks in occupational settings. Tysabri (natalizumab) is a monoclonal antibody indicated as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use is associated with a significantly increased risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV). PML typically occurs only in immunocompromised patients and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The U.S. Food and Drug Administration (FDA) has issued a boxed warning for Tysabri, stating that the drug increases the risk of PML. The warning emphasizes that healthcare professionals should monitor patients for any new sign or symptom suggestive of PML and withhold Tysabri dosing immediately at the first such indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of this risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These clinical findings underscore the need to evaluate whether similar biological mechanisms could pose risks to workers who handle Tysabri during manufacturing or administration.

Risk Factors and Mechanistic Pathway

Three primary risk factors for developing PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk for developing PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered in the context of expected benefit when initiating and continuing treatment with Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The mechanistic pathway linking Tysabri to PML involves the drug's pharmacological action. Tysabri is an alpha-4 integrin antagonist that inhibits the migration of immune cells across the blood-brain barrier. This immunosuppressive effect in the central nervous system can allow latent JCV to reactivate and cause PML. The drug's labeling explicitly states that Tysabri increases the risk of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Understanding this mechanism is crucial for assessing whether occupational exposure could similarly affect immune surveillance in the central nervous system.

Clinical Trial Evidence and Timeline of Harm

Clinical trial data provide evidence of the causal link between Tysabri and PML. In clinical trials, PML occurred in three patients who received Tysabri. Two cases were observed among 1,869 patients with multiple sclerosis who were treated for a median of 120 weeks; these two patients had received Tysabri in addition to interferon beta-1a. The third case occurred after eight doses in one of 1,043 patients with Crohn's disease who were evaluated for PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These cases demonstrate that PML can occur both in the context of combination therapy (with interferon beta-1a) and as monotherapy, and that the timeline from exposure to harm can vary, with cases reported after both shorter and longer treatment durations. This variability underscores the need for ongoing vigilance throughout treatment and raises questions about the potential for harm from repeated low-level occupational exposure.

Regulatory Warnings and Risk Mitigation

Regarding the adequacy of warnings, the FDA has mandated a boxed warning, which is the strongest warning required for prescription drugs. The warning clearly states that Tysabri increases the risk of PML, that PML usually leads to death or severe disability, and that healthcare professionals should monitor patients and withhold Tysabri immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The labeling also includes a warnings and precautions section that details the risk factors and the need for monitoring (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The TOUCH Prescribing Program further restricts distribution to ensure that prescribers, patients, and pharmacies are educated about the risks and that patients are monitored regularly. For affected patients, causation-related considerations are central. The presence of anti-JCV antibodies, duration of therapy, and prior immunosuppressant use are established risk factors that can help assess individual risk. The timeline between exposure and documented harm varies; in clinical trials, PML occurred after a median of 120 weeks in multiple sclerosis patients and after eight doses in a Crohn's disease patient (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This variability underscores the need for ongoing vigilance throughout treatment. In summary, the evidence establishes a clear causal link between Tysabri and PML, with well-defined risk factors and a documented timeline of harm. The FDA has implemented strong warnings and a restricted distribution program to mitigate this risk, but the potential for severe outcomes remains. Patients and healthcare providers must carefully weigh the expected benefits of Tysabri against the risk of PML.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the causal link between Tysabri and Progressive Multifocal Leukoencephalopathy?

Tysabri (natalizumab) increases the risk of PML, an opportunistic brain infection caused by the JC virus. Clinical trials documented PML in patients receiving Tysabri, and the FDA has issued a boxed warning. The drug's mechanism—blocking immune cell migration into the brain—can allow latent JCV to reactivate. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962)

What are the primary risk factors for developing PML while on Tysabri?

Three key risk factors are: presence of anti-JCV antibodies, longer treatment duration (especially over two years), and prior use of immunosuppressants. Anti-JCV antibody positive patients have higher risk. These factors help assess individual risk. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962)

How does the FDA warn about Tysabri-associated PML?

The FDA requires a boxed warning—the strongest warning—stating that Tysabri increases PML risk, which can lead to death or severe disability. It mandates monitoring and immediate discontinuation if PML is suspected. Tysabri is only available through the restricted TOUCH Prescribing Program. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962)

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

FDA DailyMed - Tysabri Labeling

Find Out If You Qualify for Compensation

Statutes of limitations can limit the time you have to file a claim. A records screening is free and confidential.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.